Four years after spinning out from Belgium's UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought by AbbVie for $130 million upfront.
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but investors' concerns about safety seem to be weighing on its share pric
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.